Hairy mobile leukemia (HCL) is diagnosed as an entity through the World Health Organization (WHO 2008)1 and the 2016 revision of the WHO classification of lymphoid neoplasms.2 For HCL, it's far four to five times more frequent in men than women, and accounts for two% of all leukemias, with approximately 1240 new HCL instances predicted in step with year3 in the United‐States. The few available population‐primarily based research are limited4-7 and show an ordinary age‐standardized incidence charge this is extraordinarily strong, an development of usual (OS) and relative survival (RS). It is likewise a substantially lower OS among African‐American individuals compared with other ethnic companies. Hairy cell leukemia should be differentiated from different HCL‐like issues, along with furry cell leukemia variant (HCL‐V)8 and splenic diffuse crimson pulp lymphoma (SDRPL).9 In this text, we will assessment the giant strides during the last three years within the information of the pathobiology of HCL and HCL‐like disorders. We will also update the new treatment tactics now available, mainly for sufferers with relapsed/refractory HCL.